glp-1 and binge eating disorder Tips for prescribing GLP-1s in patients with disorders New hope for binge eating

CONSUMER LAW GROUP is investigating a Canada wide class action lawsuit against Novo Nordisk Canada Inc and Eli Lilly Canada Inc in relation to their weight l

This guide explores the clinical evidence, biomarker considerations, and how providers evaluate safety when considering GLP-1 therapy for patients with inflammatory bowel disease

Nausea after eating is a common side effect of semaglutide and other GLP-1 medications, affecting up to 40% of users in clinical trials

Eli Lillys decision to hike the UK list price of its weight-loss drug Mounjaro by as much as 170% isnt just about affordability

telehealth and medically integrated programs

When patients on GLP-1 therapy also make healthy lifestyle choicesgetting enough sleep and exercising, for examplethe benefits are significantly greater.